ISET® CTC Test

About Rarecells

Rarecells is a private, commercial-stage diagnostics company pioneering a next-generation liquid biopsy platform for the ultra-early detection of cancer. Its CE-IVD-certified ISET® technology isolates circulating tumor cells (CTCs) from blood with unparalleled sensitivity, capable of detecting a single tumor cell, and is being commercialized for cancer testing in Paris. The company's R&D strategy combines CTC-DNA analysis with circulating tumor DNA (ctDNA) and AI-driven multiomics to significantly enhance detection sensitivity and genomic insight, aiming to set a new global standard in precision oncology and early intervention.

Therapeutic Areas